Is Sertraline a Substrate of P-glycoprotein?
Yes, sertraline is a high-affinity substrate of P-glycoprotein (P-gp). Both sertraline and its active metabolite desmethylsertraline demonstrate transport activity comparable to the prototypical P-gp substrate verapamil 1, 2.
Evidence for Sertraline as a P-gp Substrate
Biochemical Characterization
Sertraline exhibits high affinity for P-gp with a Vmax/Km value of 1.6 min⁻¹ × 10⁻³, which is comparable to verapamil (1.7 min⁻¹ × 10⁻³) 2.
Desmethylsertraline, the primary metabolite, also demonstrates high P-gp affinity with a Vmax/Km of 1.4 min⁻¹ × 10⁻³ 2.
P-gp preferentially transports uncharged or weakly basic molecules, and sertraline fits this substrate profile as a weakly basic compound 1.
Functional Evidence
In vitro studies using brain endothelial cells demonstrate that sertraline rapidly and potently inhibits P-gp function, as measured by increased cellular calcein accumulation 3.
In vivo mouse studies show that sertraline modulates P-gp activity at the blood-brain barrier and blood-testis barrier, with a biphasic effect: initial inhibition at 5 minutes, followed by reduced digoxin accumulation at 60 minutes, then increased accumulation again at 240 minutes 3.
Sertraline increases placental P-gp-mediated efflux after 4 hours of exposure (P < 0.001), while simultaneously decreasing P-gp efflux at the fetal blood-brain barrier (P < 0.001), demonstrating tissue-specific regulation 4.
Clinical Implications
Drug-Drug Interaction Potential
As both a P-gp substrate and modulator, sertraline may interact with other P-gp substrates including digoxin, dabigatran, colchicine, diltiazem, and morphine 5.
Concomitant use with strong P-gp inhibitors (amiodarone, verapamil, ketoconazole, quinidine, clarithromycin) could theoretically increase sertraline exposure 5.
Conversely, P-gp inducers like rifampicin and St. John's wort may reduce sertraline bioavailability 5.
Blood-Brain Barrier Considerations
P-gp is expressed at 150-180 kDa on the luminal membrane of brain capillary endothelial cells, where it normally limits CNS penetration of substrates 5, 1.
The fact that sertraline is a P-gp substrate means its brain penetration is actively regulated by this efflux transporter 6.
Important Caveats
The biphasic time-course effect observed in animal studies suggests that the clinical impact of P-gp-mediated interactions with sertraline may vary depending on timing of co-administration 3.
Tissue-specific regulation (opposite effects in placenta versus fetal BBB) indicates that P-gp interactions with sertraline cannot be predicted uniformly across all barrier sites 4.
While sertraline clearly interacts with P-gp, the clinical significance of these interactions in routine practice remains incompletely characterized, as most evidence comes from in vitro and animal studies rather than controlled human trials 2, 3, 6.